According to Fortune Business Insights, the global swine vaccines market size was valued at USD 1.85 billion in 2025. The market is projected to grow from USD 1.98 billion in 2026 to USD 3.44 billion by 2034, exhibiting a CAGR of 7.15% during the forecast period from 2026 to 2034. Rising prevalence of infectious diseases among swine, increasing adoption of preventive animal healthcare, and growing development of advanced vaccines are supporting market expansion.
The global swine vaccines market is driven by the continuing need for disease prevention across commercial pig farms. Vaccine manufacturers are expanding beyond conventional products by developing combination vaccines, recombinant technologies, advanced antigen designs, and novel delivery platforms.
The market encompasses modified-live attenuated vaccines, inactivated vaccines, bacterins and toxoid-based vaccines, recombinant subunit and virus-like particle vaccines, viral-vector and chimeric vaccines, and newer nucleic-acid and replicon technologies.
The industry is also becoming increasingly connected with digital animal-health systems. Electronic animal identification, digital traceability, herd-health monitoring, and needle-free vaccination technologies are helping producers and veterinarians improve vaccination accuracy and monitor health outcomes.
For detailed market insights: https://www.fortunebusinessinsights.com/swine-vaccines-market-118648
A significant trend in the swine vaccines market is the integration of vaccination with digital herd-management technologies. Digital identification, traceability, vaccination records, and monitoring systems enable producers to track individual animals and evaluate vaccination effectiveness.
For example, MSD Animal Health showcased its “Swine Protect & Connect” approach in 2025, integrating an intradermal vaccine with needle-free vaccination devices and digital identification and monitoring technology. Such developments demonstrate the industry's movement toward connected and data-driven preventive healthcare.
Manufacturers are increasingly developing combination vaccines, recombinant vaccines, advanced antigen designs, and novel delivery technologies. These platforms can provide broader strain coverage and simplify vaccination schedules.
The nucleic-acid and replicon vaccines segment is expected to record a 14.21% CAGR during the forecast period, highlighting the growing interest in newer vaccine technologies.
The persistent prevalence and economic impact of swine diseases remain the leading growth driver. PRRS, porcine circovirus-associated diseases, Mycoplasma hyopneumoniae, swine dysentery, and other respiratory and gastrointestinal infections can cause mortality, reproductive losses, slower weight gain, increased treatment expenses, and lower feed efficiency.
As a result, commercial producers are increasingly relying on preventive vaccination to limit disease transmission and protect productivity. Continued pathogen evolution and changing disease epidemiology are also encouraging manufacturers to develop vaccines with broader coverage.
Growing commercial pig production in emerging markets is creating additional demand for preventive animal-health products. Increasing vaccination coverage across Asia, Latin America, and Africa is opening opportunities for manufacturers, particularly as governments and producers strengthen disease-control programs.